13
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Driver mutations in USP8 wild-type Cushing’s disease

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Medical treatment in Cushing’s disease (CD) is limited due to poor understanding of its pathogenesis. Pathogenic variants of ubiquitin specific peptidase 8 (USP8) have been confirmed as causative in around half of corticotroph tumors. We aimed to further characterize the molecular landscape of those CD tumors lacking USP8 mutations in a large cohort of patients.

          Methods

          Exome sequencing was performed on 18 paired tumor–blood samples with wild-type USP8 status. Candidate gene variants were screened by Sanger sequencing in 175 additional samples. The most frequent variant was characterized by further functional in vitro assays.

          Results

          Recurrent somatic hotspot mutations in another deubiquitinase, USP48, were found in 10.3% of analyzed samples. Several possibly damaging variants were found in TP53 in 6 of 18 samples. USP48 variants were associated with smaller tumors and trended toward higher frequency in female patients. They also changed the structural conformation of USP48 and increased its catalytic activity toward its physiological substrates histone 2A and zinc finger protein Gli1, as well as enhanced the stimulatory effect of corticotropin releasing hormone (CRH) on pro-opiomelanocortin production and adrenocorticotropic hormone secretion.

          Conclusions

          USP48 pathogenic variants are relatively frequent in USP8 wild-type tumors and enhance CRH-induced hormone production in a manner coherent with sonic hedgehog activation. In addition, TP53 pathogenic variants may be more frequent in larger CD tumors than previously reported.

          Related collections

          Most cited references35

          • Record: found
          • Abstract: found
          • Article: not found

          The genomic landscapes of human breast and colorectal cancers.

          Human cancer is caused by the accumulation of mutations in oncogenes and tumor suppressor genes. To catalog the genetic changes that occur during tumorigenesis, we isolated DNA from 11 breast and 11 colorectal tumors and determined the sequences of the genes in the Reference Sequence database in these samples. Based on analysis of exons representing 20,857 transcripts from 18,191 genes, we conclude that the genomic landscapes of breast and colorectal cancers are composed of a handful of commonly mutated gene "mountains" and a much larger number of gene "hills" that are mutated at low frequency. We describe statistical and bioinformatic tools that may help identify mutations with a role in tumorigenesis. These results have implications for understanding the nature and heterogeneity of human cancers and for using personal genomics for tumor diagnosis and therapy.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            Recurrent gain-of-function USP8 mutations in Cushing's disease

            Cushing's disease, also known as adrenocorticotropic hormone (ACTH)-secreting pituitary adenomas (PAs) that cause excess cortisol production, accounts for up to 85% of corticotrophin-dependent Cushing's syndrome cases. However, the genetic alterations in this disease are unclear. Here, we performed whole-exome sequencing of DNA derived from 12 ACTH-secreting PAs and matched blood samples, which revealed three types of somatic mutations in a candidate gene, USP8 (encoding ubiquitin-specific protease 8), exclusively in exon 14 in 8 of 12 ACTH-secreting PAs. We further evaluated somatic USP8 mutations in additional 258 PAs by Sanger sequencing. Targeted sequencing further identified a total of 17 types of USP8 variants in 67 of 108 ACTH-secreting PAs (62.04%). However, none of these mutations was detected in other types of PAs (n = 150). These mutations aggregate within the 14-3-3 binding motif of USP8 and disrupt the interaction between USP8 and 14-3-3 protein, resulting in an elevated capacity to protect EGFR from lysosomal degradation. Accordingly, PAs with mutated USP8 display a higher incidence of EGFR expression, elevated EGFR protein abundance and mRNA expression levels of POMC, which encodes the precursor of ACTH. PAs with mutated USP8 are significantly smaller in size and have higher ACTH production than wild-type PAs. In surgically resected primary USP8-mutated tumor cells, USP8 knockdown or blocking EGFR effectively attenuates ACTH secretion. Taken together, somatic gain-of-function USP8 mutations are common and contribute to ACTH overproduction in Cushing's disease. Inhibition of USP8 or EGFR is promising for treating USP8-mutated corticotrophin adenoma. Our study highlights the potentially functional mutated gene in Cushing's disease and provides insights into the therapeutics of this disease.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              ATRX and DAXX: Mechanisms and Mutations

              Recent genome sequencing efforts in a variety of cancers have revealed mutations and/or structural alterations in ATRX and DAXX , which together encode a complex that deposits histone variant H3.3 into repetitive heterochromatin. These regions include retrotransposons, pericentric heterochromatin, and telomeres, the latter of which show deregulation in ATRX / DAXX -mutant tumors. Interestingly, ATRX and DAXX mutations are often found in pediatric tumors, suggesting a particular developmental context in which these mutations drive disease. Here we review the functions of ATRX and DAXX in chromatin regulation as well as their potential contributions to tumorigenesis. We place emphasis on the chromatin remodeler ATRX, which is mutated in the developmental disorder for which it is named, α-thalassemia, mental retardation, X-linked syndrome, and at high frequency in a number of adult and pediatric tumors. The chromatin remodeler ATRX and the histone chaperone DAXX are often mutated in cancer, but it is unclear whether they drive pathogenesis. Work to define their roles in cell biology, development, and disease is ongoing.
                Bookmark

                Author and article information

                Journal
                Neuro Oncol
                Neuro-oncology
                neuonc
                Neuro-Oncology
                Oxford University Press (US )
                1522-8517
                1523-5866
                October 2019
                19 June 2019
                19 June 2019
                : 21
                : 10
                : 1273-1283
                Affiliations
                [1 ] Department of Medicine I, Division of Endocrinology and Diabetes, University Hospital Würzburg (UKW) , Würzburg, Germany
                [2 ] Comprehensive Cancer Center Mainfranken, University of Würzburg , Würzburg, Germany
                [3 ] Medizinische Klinik und Poliklinik IV, Ludwig-Maximilians-Universität (LMU) München , Munich, Germany
                [4 ] Department of Clinical Tumor Biology, University Hospital, University of Tübingen , Tübingen, Germany
                [5 ] Department of Neurosurgery, University Hospital Hamburg-Eppendorf , Hamburg, Germany
                [6 ] Institute of Human Genetics, Helmholtz Zentrum München , Neuherberg, Germany
                [7 ] Department of Neuropathology, Institute of Pathology, University of Würzburg , Würzburg, Germany
                [8 ] Institute for Neuropathology, University Hospital Hamburg-Eppendorf , Hamburg, Germany
                [9 ] Department of Neurosurgery, Eberhard Karls University Tübingen , Tübingen, Germany
                [10 ] Inserm Unit 1016, National Center for Scientific Research Joint Research Unit, Cochin Institute, Paris Descartes University , Paris, France
                [11 ] Department of Internal Medicine, Division of Endocrinology, Radboud University Medical Centre , Nijmegen, the Netherlands
                [12 ] Medicover Neuroendocrinology , Munich, Germany
                [13 ] Clinical Chemistry and Laboratory Medicine, University Hospital Würzburg , Würzburg, Germany
                [14 ] Institute of Metabolism and System Research, University of Birmingham , Birmingham, UK
                [15 ] Institute of Human Genetics, Technische Universität München , Munich, Germany
                [16 ] Comprehensive Heart Failure Center, University of Würzburg , Würzburg, Germany
                Author notes
                Corresponding Authors: Prof Martin Fassnacht, MD, Division of Endocrinology and Diabetes, University Hospital of Wuerzburg, Oberduerrbacherstr. 6, 97080 Wuerzburg, Germany ( Fassnacht_M@ 123456ukw.de ); Prof. Marily Theodoropoulou, PhD, Medizinische Klinik und Poliklinik IV, Ludwig Maximilian University Munich, Ziemssenstr. 1, 80336 Munich, Germany ( marily.theodoropoulou@ 123456med.uni-muenchen.de ).

                These authors contributed equally.

                Author information
                http://orcid.org/0000-0002-6271-5533
                Article
                noz109
                10.1093/neuonc/noz109
                6784271
                31222332
                35f7687d-4de6-4996-8949-a80a0fa18d3f
                © The Author(s) 2019. Published by Oxford University Press on behalf of the Society for Neuro-Oncology.

                This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

                History
                : 12 July 2019
                Page count
                Pages: 11
                Funding
                Funded by: German Research Foundation 10.13039/501100001659
                Award ID: FA 466/5-1
                Award ID: DE 2657/1-1
                Award ID: PO1458/5-1
                Funded by: SFB Transregio
                Award ID: CRC/TRR 205/1
                Categories
                Basic and Translational Investigations

                Oncology & Radiotherapy
                cushing’s disease,genome sequencing,driver mutations,usp48,tp53
                Oncology & Radiotherapy
                cushing’s disease, genome sequencing, driver mutations, usp48, tp53

                Comments

                Comment on this article